SCHEMBL6068271

SCHEMBL6068271

CCNC(=O)Nc1nc2ccc(Oc3ccc(F)cc3)cc2s1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 11/20 0.65
NPC1 O15118 5/20 0.58
RAB9A P51151 5/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
SCD O00767 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
PIK3CA P42336 1/20 0.57
PIK3CG P48736 1/20 0.57
PTPN1 P18031 1/20 0.54
USP2 O75604 1/20 0.53
POLB P06746 1/20 0.53
MAPT P10636 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
PIK3CD O00329 1/20 0.53
PDPK1 O15530 1/20 0.53
DYRK1A Q13627 1/20 0.53
TSHR P16473 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1282877 0.85 ABL1 (0.83) ABL1NPC1RAB9AMEN1KMT2A
SCHEMBL6068154 0.84 CACNA1B (0.52) ABL1NPC1RAB9AMEN1KMT2A
SCHEMBL6068149 0.83 ABL1 (0.60) ABL1NPC1RAB9ASMN1; SMN2PIK3CA
SCHEMBL6067851 0.82 NPC1 (0.61) NPC1RAB9AMEN1KMT2ASCD
SCHEMBL6068022 0.82 ABL1 (0.59) ABL1NPC1RAB9AMEN1KMT2A
SCHEMBL6067799 0.82 ABL1 (0.59) ABL1NPC1RAB9ASMN1; SMN2PIK3CA
SCHEMBL6068028 0.82 ABL1 (0.59) ABL1NPC1RAB9AMEN1KMT2A
SCHEMBL6068373 0.82 ABL1 (0.59) ABL1NPC1RAB9AMEN1KMT2A
SCHEMBL6067958 0.81 NPC1 (0.48) ABL1NPC1RAB9AMEN1KMT2A
SCHEMBL6068180 0.81 ABL1 (0.57) ABL1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091227-B2 Benzothiazole derivatives ABBOTT GMBH & CO. KG (DE) 2006-08-15 US disclosed
US-20030153568-A1 Benzothiazole derivatives BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY 2003-08-14 US disclosed
EP-1254123-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS Abbott GmbH & Co. KG (DE) 2002-11-06 EP disclosed
WO-2001057008-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153568-A1 Benzothiazole derivatives TK1, FLT1, CDK1 ABL1 7/4885NPC1 3594/4885RAB9A 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.